L'intérêt à découvert pour Exelixis donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Exelixis. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Exelixis (NASDAQ:EXEL) Stock, Rapport sur les intérêts à découvert

Exelixis

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis Inc

EXELIXIS ORD

EXELON ORD

Exela Technologies Inc

Exela Technologies, Inc. - 6.00% Series B Cumulative Convertible Perpetual Preferred Stock

Exelon Corp

Shares of Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>) have risen 20.7% in the past three months compared with the industry&#39;s growth of 6.3%. The stock has also outperformed the sector and the S&amp;P 500 Index.
Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.
<h2>EXEL Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9a/80573.jpg?v=2113034342" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Cabometyx Boosts EXEL</h2>
Cabometyx maintained its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in 2023. This was mainly attributable to its use in combination with Bristol Myers&#39;&nbsp;Opdivo in the first-line setting. The drug also maintained growth in the hepatocellular carcinoma indication.
BMY&#39;s Opdivo is one of the leading immuno-oncology drugs, approved for various oncology indications.
Management is also focused on the label expansion of Cabometyx. The FDA accepted EXEL&#39;s supplemental new drug application (sNDA) for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET.
A potential label expansion should further propel its growth prospects.
Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq (atezolizumab), for metastatic castration-resistant prostate cancer.
<h2>EXEL Makes Encouraging Pipeline Progress</h2>
The pipeline progress has been impressive as well, as Exelixis looks to expand its oncology portfolio beyond Cabometyx.
Other promising candidates in Exelixis&#39; pipeline zanzalintinib, a next-generation oral TKI and XL309. In the first half of 2025, Exelixis intends to initiate a phase III study, STELLAR-311, to evaluate zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET.
The company also plans to advance phase I efforts for XL309 and XB010.
EXEL decided to discontinue the development of XB002. It plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.
The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Exelixis&#39; Efforts to Boost Shareholder Value</h2>
Exelixis is also making efforts to increase shareholder value through repurchases.&nbsp; At the end of the second quarter, Exelixis completed its 2024 share repurchase program, having repurchased 20.3 million shares of the company&#39;s common stock for a total of $450 million.
Consequently, the company returned $1 billion to shareholders since the initial $550 million stock repurchase program was authorized in March 2023.
The board of directors has authorized the repurchase of up to an additional $500 million of the company&#39;s common stock through the end of 2025.
<h2>Valuation &amp; Estimates</h2>
Going by the price/sales ratio, EXEL&#39;s shares currently trade at 3.64x forward sales, higher than its mean of 3.34x and the biotech industry&#39;s 1.79x.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/80575.jpg?v=206418566" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has increased to $1.83 from $1.79 over the past 30 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/80578.jpg?v=1325426803" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Large biotech companies are generally considered safe havens for investors interested in this sector. EXEL is a good stock to buy now, with good fundamentals and growth prospects.
The stock has performed well this year. Potential label expansion of Cabometyx should boost its growth. The company&#39;s efforts to expand its portfolio are encouraging as well. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Zacks Rank &amp; Other Key Picks</h2>
EXEL currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) and Krystal Biotech (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), both carrying a Zacks Rank #1 (Strong Buy) at present.
ALNY&#39;s loss per share estimate for 2024 has narrowed from $1.20 to 63 cents in the past 60 days and the same for 2025 has narrowed from 34 cents to 27 cents.
Krystal Biotech&#39;s earnings per share for 2024 have increased to $2.38 from $1.98 in the past 90 days. Shares of KRYS have surged 42.8% year to date.
<a href="https://www.zacks.com/stock/news/2346907/exelixis-gains-20-7-in-three-months-is-this-the-right-time-to-buy?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346907">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Large Cap

Mid Cap

News

Management

Markets

Analyst Ratings

Trading Ideas

General

ALNY

EXEL

KRYS

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Across the recent three months, 9 analysts have shared their insights on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.22, a high estimate of $33.00, and a low estimate of $27.00. Observing a 2.96% increase, the current average has risen from the previous average price target of $28.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1728065106_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Exelixis's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exelixis's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Delving into Exelixis's Background</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of 35.61% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 35.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exelixis's ROE excels beyond industry benchmarks, reaching 10.65%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Exelixis Analyst Ratings

RBC Capital analyst Gregory Renza maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $27 to $30.

Price Target

RBC Capital Maintains Outperform on Exelixis, Raises Price Target to $30

RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and maintains $27 price target.

Reiteration

RBC Capital Reiterates Outperform on Exelixis, Maintains $27 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $29 price target.

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $29 Price Target

UBS analyst Ashwani Verma initiates coverage on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Neutral rating and announces Price Target of $30.

Initiation

UBS Initiates Coverage On Exelixis with Neutral Rating, Announces Price Target of $30

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Exelixis and provided 12-month price targets. The average target is $29.4, accompanied by a high estimate of $33.00 and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 2.08% increase from the previous average price target of $28.80.
<img src="https://www.benzinga.com/files/images/story/2024/1726660908_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Exelixis among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Exelixis's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exelixis's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Get to Know Exelixis Better</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Understanding the Numbers: Exelixis's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 35.61%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 35.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.11%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For Exelixis

HC Wainwright &amp; Co. analyst Robert Burns reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and maintains $29 price target.

HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $29 Price Target

– Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with advanced neuroendocrine tumors, including across key subgroups –
– Findings were the basis for the supplemental New Drug Application filed with the U.S. Food and Drug Administration for cabozantinib for advanced neuroendocrine tumors –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54121961&amp;newsitemid=20240913607414&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=4f8379ba502429acd448e5b9f9cf84ab">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX&#xAE;) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with advanced pancreatic neuroendocrine tumors (pNET) and one cohort with advanced extra-pancreatic NET (epNET). These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper Session: NETs and Endocrine Tumours at 2:45 p.m. CET and were simultaneously published in the New England Journal of Medicine (NEJM).

Exelixis Announces Final Results From Phase 3 Pivotal CABINET Study Evaluating Cabozantinib In Advanced Neuroendocrine Tumors Presented At ESMO 2024 And Published In New England Journal Of Medicine

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54121999&amp;newsitemid=20240913609179&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=84066b887b55d0760e884a453fdc4619">Exelixis, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX&reg;) in combination with atezolizumab (Tecentriq&reg;) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT. These data are being presented today at the 2024 European Society for Medical Oncology Congress (ESMO 2024) during the Proffered Paper Session: GU Tumours, Prostate at 2:45 p.m. CEST.

Reported Sunday, Exelixis Presents Final Phase 3 CONTACT-02 Survival Data For Cabozantinib Combo In Metastatic Prostate Cancer At ESMO 2024

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Exelixis and provided 12-month price targets. The average target is $28.2, accompanied by a high estimate of $33.00 and a low estimate of $23.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.91%. 
<img src="https://www.benzinga.com/files/images/story/2024/1723143994_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Exelixis among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Delving into Exelixis's Background</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Financial Insights: Exelixis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exelixis displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 35.61%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 35.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.11%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Exelixis Through The Eyes Of 5 Analysts

Truist Securities analyst Asthika Goonewardene reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $32 to $33.

Truist Securities Reiterates Buy on Exelixis, Raises Price Target to $33

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and raises the price target from $27 to $29.

JMP Securities Maintains Market Outperform on Exelixis, Raises Price Target to $29

In its second-quarter earnings release, Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40201498/exelixis-announces-second-quarter-2024-financial-results-and-provides-corporate-update" rel="noreferrer noopener">trial has been completed</a>.
This study evaluates cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable soft-tissue disease who have progressed after treatment with one prior NHT.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36741223/bristol-myers-exelixis-reveal-4-year-follow-up-results-from-cancer-treatment-study" rel="noreferrer noopener">Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study</a>.
As previously reported, the CONTACT-02 study met one of its two primary endpoints, demonstrating a statistically significant benefit in progression-free survival (PFS) (hazard ratio: 0.65; p=0.0007) in the predefined PFS intent-to-treat population (i.e., <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33965662/third-time-lucky-exelixis-cabozantinib-combo-therapy-aces-pivotal-study-in-prostate-cancer-patien" rel="noreferrer noopener">the first 400 randomized patients)</a>.
While the final OS continued to favor the combination of cabozantinib and atezolizumab, it did not achieve statistical significance.
The safety profile of the combination regimen was reflective of the known safety profiles for each single agent and was consistent with the known tolerability profile of approved immune checkpoint inhibitor-tyrosine kinase inhibitor combinations in advanced solid tumors.&nbsp;
Despite the trial update, the company intends to submit a supplemental marketing application to the FDA in 2024.
Exelixis reported second-quarter adjusted EPS of $0.84, higher than $0.31 a year ago, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $0.30</a>.
The sales increased to $637.2 million, beating the consensus of $465 million, up from $469.8 million a year ago, primarily due to increased sales volume and average net selling price.
Guidance: Exelixis sees 2024 revenues of $1.975 billion—$2.075 billion versus a consensus of $1.88 billion and prior guidance of $1.825 billion—$1.925 billion.
William Blair writes that Exelixis has entered 2024 at an inflection point. The growth of its flagship Cabometyx franchise is stabilizing, while pipeline programs, especially zanzalintinib, are increasingly responsible for offsetting Cabometyx's market exclusivity expiry in 2031.
In the midterm, NETs and mCRPC could emerge as material growth opportunities for the franchise.
&#8220;Ultimately, given the cash flow generation and EPS positivity, we believe Exelixis provides investors with a highly defensive investment profile,&#8221; the analyst adds.
The analyst reiterates the Outperform rating on Exelixis shares.
Price Action: EXEL stock is up 13% at $26.49 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40222523/charles-river-laboratories-stock-sinks-as-it-warns-of-continued-biotech-demand-slump-lowers-forecas" target="_blank" rel="noreferrer noopener">Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast</a>.</li>
</ul>

Analyst Color

Equities

Guidance

Health Care

Movers

Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results

WIIM

Exelixis shares are trading higher after the company reported better-than-expected Q2 and issued FY24 revenue guidance above estimates.

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by another sharp slide in the CBOE Volatility Index, which is now approaching pre-sell-off levels. <a href="https://www.benzinga.com/news/earnings/24/08/40213937/why-ai-server-maker-super-micro-computers-stock-is-plummeting-over-12-in-premarket">Earnings news of the day has been mixed,</a> with the Dow Jones Industrials likely to take a hit from negative reactions to earnings reports from Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) and Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) may weigh down on AI-levered stocks as traders sold the AI server maker due to margin contraction. That said, the broader sentiment appears to be positive as traders pile into beaten-down stocks to position themselves for a strong rebound they factor in for later this year.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+1.50%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+1.22%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.85%</td>
</tr>
<tr>
<td>R2K</td>
<td>+1.74%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">In premarket trading on Wednesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 1.30% to $528.95, and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) jumped 1.58% to $446.48, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.</figcaption></figure>
Cues From Last Session:
Stocks rebounded from multi-week lows and launched into a rally as traders scrambled to pick bargains across sectors. The market slowly got over the trauma inflicted by weakening domestic economic fundamentals and the selling set in motion by the unwinding of the yen carry trades.
The major averages opened mostly lower and saw some indecision in early trading. They took off, benefiting from across-the-board buying, and hovered in positive territory all through the remainder of the session. The gains were led by real-estate stocks. 
Small-caps outperformed their bigger peers, with the Russell 2,000 Index ending 1.23% higher for the day.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+1.03%</td>
<td>16,366.85</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+1.04%</td>
<td>5,240.03</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.76%</td>
<td>38,997.66</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+1.23%</td>
<td>2,064.30</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> Insights From Analysts: Following Tuesday&#8217;s comeback, Fund Strat said the rebound by equities is very constructive and strongly supports the idea the &#8216;worst of the selling is behind us,&#8217; according to excerpts of the note shared on X, formerly Twitter. Tom Lee, Head Of Research at the firm, said in a separate post that it was a &#8220;rough 3 days of relentless selling but instead of breaking equity markets, VIX falling, BOJ pausing hikes, stocks finding footing.&#8221; &#8220;Seems more &#8216;growth scare&#8217; not calamity.&#8221; George Smith, portfolio strategist at LPL Financial, said dips, pullbacks and corrections of 10% or more are a &#8220;normal and healthy part of any bull market.&#8221; Falling back on historical data, Smith noted that on average, stocks experience a pullback of over 5% over three times per year and a correction of 10% or more around once per year, even in positive years. &#8220;We believe that how common these occurrences are should provide comfort to equity investors, allowing them to be patient, stay invested, and most importantly, to not panic,&#8221; he added. Upcoming Economic Data: The Energy Information Administration will release its weekly petroleum status report at 10:30 a.m. EDT. The Federal Reserve is scheduled to release its report on June consumer credit at 3 p.m. EDT. Economists, on average, expect the outstanding consumer credit to decline from $11.3 billion in May to $9.7 billion in June. See also: <a href="https://www.benzinga.com/money/best-futures-trading-software">Best Futures Trading Software</a> Stocks In Focus: Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) fell over 16% <a href="https://www.benzinga.com/premarket">in premarket trading</a> following its quarterly results, while Super Micro plunged over 14%, also on earnings. The other stocks moving on earnings are Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) (up over 4.50%), Amgen (down over 4.50%), Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) (up nearly 12%), Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) (up over 6.50%), Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) (up over 16%), Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) (up over 6%), Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) (down over 16%), Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) (down over 6.50%), Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) (down nearly 8%), Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) (up over 12%), Trex Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) (down nearly 17%), and Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) (up over 4.50%). CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>), Disney and Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>)are among the key companies due to <a href="https://www.benzinga.com/calendars/earnings">release their earnings reports ahead of the market opening</a>. Those reporting after the close are AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>), Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>), Blink Charging Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>), Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>), Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>), HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>), Kulicke and Soffa Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLIC#NASDAQ">KLIC</a>), Marathon Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>), Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>). Commodities, Bonds And Global Equity Markets: Crude oil futures rose sharply, extending the gains from the previous session, and gold futures rebounded, while the yield on the 10-year Treasury note rose 4.9 basis points to 3.936%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) pushed up about 4%, past the $57K mark. Asian markets climbed across the board, led by the Taiwanese, South Korean, Singaporean and Hong Kong markets. The Australian and Chinese markets underperformed with much more modest gains, with the latter stymied by weak export data that offset the rebound in imports. European stocks also rallied hard in early trading. Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40212775/move-over-yen-yuan-carry-trades-could-be-next-ticking-bomb-warns-strategists-but-it">Move Over Yen, Yuan Carry Trades Could Be Next Ticking Bomb, Warns Strategists: &#8216;But It&#8217;s Below The Danger Levels We Monitor&#8217;</a></figcaption></figure>
Image generated using AI via Midjourney

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

$BTC

ABNB

AMGN

BLNK

BMBL

BYND

CRUS

FSLY

FTNT

FWRD

HOOD

HUBS

ILMN

KLIC

LYFT

MNST

RDDT

RIVN

SHOP

SMCI

TREX

TRIP

WYNN

US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'

Exelixis Sees 2024 Total Revenues $1.975B-$2.075B vs $1.88B Est.

Exelixis shares are trading higher after the company reported better-than-expected Q2.

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.30 by 180 percent. The company reported quarterly sales of $637.178 million which beat the analyst consensus estimate of $465.005 million by 37.03 percent. This is a 35.61 percent increase over sales of $469.848 million the same period last year.

Earnings Beats

Exelixis Q2 2024 Adj. EPS $0.84 Beats $0.30 Estimate, Sales $637.178M Beat $465.005M Estimate

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on September 6. Analyst Derek Archila from...

Optimistic Outlook for Exelixis with Growth Opportunities in Drug Development Pipeline

Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on Exelixis (EXEL – Research Report). The associated price target remains the...

Exelixis (EXEL) Stock Buy Rating Affirmed on Promising Subgroup Data and Market Opportunity in mCRPC Treatment

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $29.00. Robert Bu...

Buy Rating on Exelixis: Optimism Fueled by Cabozantinib's Trial Success and Near-Term Catalysts

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target ...

Exelixis (EXEL) Gets a Hold from Stifel Nicolaus

Exelixis unveils additional data on Cabometyx for neuroendocrine tumors

IHF: Healthcare Dashboard For September

ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life

Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Exelixis (EXEL – Research Report). The associated price target remain...

Exelixis Growth Prospects: A Buy Rating Based on Robust NET Clinical Data and Market Potential

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $27...

RBC Capital Reaffirms Their Buy Rating on Exelixis (EXEL)

JMEE: Actively Managed ETF In Line With Its Objective

ALKS

BNTX

CACI

COHR

COLL

DSKYF

DSNKY

GEHC

HRMY

INVA

JHMM

JMEE

MDYG

MDYV

PSTG

RHHBY

TNGX

UTHR

VEEV

XMMO

Opinion

Press Releases

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond

Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Comments

Exelixis

Intérêt court

Exelixis (NASDAQ:EXEL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL